Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2529 The University of Texas at San Antonio (144417)
Principal Investigator: Wang, Yufeng
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 22,000
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 10/1/22 - 9/30/23
Restricted Research: YES
Academic Discipline: SCIENCES
Department, Center, School, or Institute: Cos Molecular Microbiology & I
Title of Contract, Award, or Gift: Optimizing host-directed therapies for infections
Name of Granting or Contracting Agency/Entity:
Texas Biomedical Research Institute
CFDA: 0
Program Title: none
Note:
SAMs 1.1.1; This research project will identify novel effectors and pathways regulated by the NR4As, and determine if the NR4As and the pathways they regulate can be targeted to control TB. This project leverages state-of the art technology and personnel that are experts in their fields, led by Drs. Arnett and Schlesinger at Texas Biomed (animal and in vitro TB models), Dr. Lai at UTHealth San Antonio (next-generation RNA sequencing), Dr. Wang at UTSA (RNA sequencing and pathway analysis), and Dr. Bohmann at SwRI (in silico modeling). The research identifies pathways regulated by the NR4As during M.tb infection using next generation RNA sequencing to provide the first comprehensive and unbiased transcriptomic characterization of macrophage responses that are altered by the NR4As; 2) Optimize agonists for the NR4As and their identified effectors using in silico modeling; and 3) Determine if agonists for the NR4As and their effectors limit M.tb growth in human and murine macrophages, and mice. This project has the potential to elevate San Antonio as a hub for biomedical research and will have major social impact by improving the health and livelihood of millions of people in the US and worldwide, including 37 million people with diabetes, 54 million people over 65 years old, the 1.8 million new cases of cancer per year and the 2.8 million new antibiotic-resistant infections each year in the US, including the continuing scourges of TB and COVID.
Discussion: No discussion notes